Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2014

View Archived Issues

ATG5, COL1A1 and CAV1 polymorphisms associated with esophageal cancer prognosis

Medivation and OncoFusion to research compounds targeting BET proteins

OXPHOS inhibitors: a novel class of oncology therapeutics

Cell Pouch device demonstrates continued biocompatibility in type 1 diabetes study

Preclinical and early clinical data presented for JNJ-42756493

F-17727 shows antifibrillatory effects in vivo

CHMP recommends variation to marketing authorization of Invega

FDA clears BrainStorm Cell Therapeutics' phase II trial of NurOwn in ALS

Anoro Ellipta launched in the U.S. for treatment of COPD

Mologen reports data from safety trial of MGN-1703

First patient treated in a phase II study evaluating CV-301 in bladder cancer

Control of multiple sclerosis-related central inflammation with ATX-MS-1467

Merck KGaA reports outcome of phase IIIb study of Kuvan

Agenus to identify anticancer antibodies for Merck & Co

Sanofi Pasteur reports data from first of two efficacy studies of tetravalent dengue vaccine

Roche receives E.U. approval for new formulation of RoActemra

Phase I results of attenuated malaria PfSPZ vaccine presented

Interim data disclosed from phase II ulcerative colitis trial of MultiStem

Janssen patent reports new IFN inducers

New histone demethylase inhibitors designed by EpiTherapeutics

European approval for BioMarin's Vimizim for Morquio A syndrome

Dainippon Sumitomo Pharma presents new nACh receptor PAMs

Investigators from the University of Utah patent novel BTK inhibitors

Novartis will not exercise option for rights to Transgene's TG-4010

Topline data reported from SYNERGY study of custirsen in metastatic CRPC

GSK's inhaled umeclidinium approved in E.U. for COPD